These clinical trials include CAR-T cells targeting CD44v6 in stomach cancer lymphosarcoma, AML, and multiple myeloma; CD133 in relapsed and/or chemotherapy refractory advanced malignancies; c-Met in patients with melanoma and breast carcinoma [179], EpCAM in nasopharyngeal carcinoma, breast cancer, gastric cancer and other EpCAM positive solid tumors (Table 2). Here, EPCAM is linked to plasma cell myeloma.